Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ULBP2-aCD19-aCD33
- Development stage
- Preclinical
- Lead developer
- University of Cologne
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**ULBP2-aCD19-aCD33** is a preclinical recombinant trispecific immunoligand, or triplebody, designed to redirect natural killer cells against leukemic cells expressing CD19, CD33, or both antigens. It combines the natural NKG2D ligand UL16-binding protein 2 with anti-CD19 and anti-CD33 single-chain variable fragments. By binding NKG2D on natural killer cells while simultaneously engaging CD19 and CD33 on malignant cells, it promotes natural killer cell-mediated cytotoxicity and may mitigate single-antigen escape. Published work demonstrated activity against CD19/CD33-positive leukemia cell lines and primary leukemic blasts, including biphenotypic B/myeloid leukemia specimens, but also identified potential on-target effects against CD33-expressing natural killer cells and normal CD19-positive B cells.
- Other names
- ULBP2-aCD19-aCD33 triplebodyULBP-2-aCD19-aCD33 triplebodyULBP 2-aCD19-aCD33 triplebody
02
Targets
CD19 (B lymphocyte antigen CD19)CD33 (Myeloid cell surface antigen CD33)ULBP2 (UL16-binding protein 2)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on ULBP2-aCD19-aCD33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ULBP2-aCD19-aCD33.